Cost-Effective Whole Transcriptome Sequencing Landscape and Diagnostic Potential Biomarkers in Active Tuberculosis

Tuberculosis (TB) is a prevalent and severe infectious disease that poses a significant threat to human health. However, it is frequently disregarded as there are not enough quick and accurate ways to diagnose tuberculosis. Here, we develop a strategy for tuberculosis detection to address the challe...

Full description

Saved in:
Bibliographic Details
Published in:ACS infectious diseases 2024-06, Vol.10 (6), p.2318-2332
Main Authors: Sun, Zaiqiao, He, Boxiao, Yang, Zhifeng, Huang, Yi, Duan, Zhaoyu, Yu, Chengyi, Dan, Zhaokui, Paek, Chonil, Chen, Peng, Zhou, Jin, Lei, Jun, Wang, Feng, Liu, Bing, Yin, Lei
Format: Article
Language:English
Subjects:
Adult
Biomarkers - analysis
Biomarkers - blood
Cost-Benefit Analysis
Female
Gene Expression Profiling - methods
Humans
Latent Tuberculosis - diagnosis
Leukocytes, Mononuclear
Male
Mycobacterium tuberculosis - genetics
Transcriptome
Tuberculosis - diagnosis
Tuberculosis - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis (TB) is a prevalent and severe infectious disease that poses a significant threat to human health. However, it is frequently disregarded as there are not enough quick and accurate ways to diagnose tuberculosis. Here, we develop a strategy for tuberculosis detection to address the challenges, including an experimental strategy, namely, Double Adapter Directional Capture sequencing (DADCSeq), an easily operated and low-cost whole transcriptome sequencing method, and a computational method to identify hub differentially expressed genes as well as the diagnosis of TB based on whole transcriptome data using DADCSeq on peripheral blood mononuclear cells (PBMCs) from active TB and latent TB or healthy control. Applying our approach to create a robust and stable TB multi-mRNA risk probability model (TBMMRP) that can accurately distinguish active and latent TB patients, including active TB and healthy controls in clinical cohorts, this diagnostic biomarker was successfully validated by several independent cross-platform cohorts with favorable performance in differentiating active TB from latent TB or active TB from healthy controls and further demonstrated superior or similar diagnostic accuracy compared to previous diagnostic markers. Overall, we develop a low-cost and effective strategy for tuberculosis diagnosis; as the clinical cohort increases, we can expand to different disease kinds and learn new features through our disease diagnosis strategy.
ISSN:2373-8227
2373-8227
DOI:10.1021/acsinfecdis.4c00374